突变体
癌症研究
癌症
激酶
肺癌
蛋白激酶A
细胞周期蛋白依赖激酶4
医学
酶抑制剂
细胞周期蛋白依赖激酶9
丝裂原活化蛋白激酶激酶
化学
蛋白激酶抑制剂
ASK1
生物
蛋白激酶结构域
细胞
突变
作用机理
MAP激酶激酶激酶
药理学
分子生物学
抑制器
酪氨酸激酶抑制剂
作者
Jieun Son,Jaebong Jang,Tyler S. Beyett,Yoonji Eum,Heidi M. Haikala,Alyssa L. Verano,Mika Lin,John M. Hatcher,Nicholas P. Kwiatkowski,Pinar Ö. Eser,Michael J. Poitras,Stephen Wang,Man Xu,Prafulla C. Gokhale,Michael D. Cameron,Michael J. Eck,Nathanael S. Gray,Pasi Antero Janne
出处
期刊:Cancer Research
[American Association for Cancer Research]
日期:2022-02-11
卷期号:82 (8): 1633-1645
被引量:49
标识
DOI:10.1158/0008-5472.can-21-2693
摘要
In-frame insertions in exon 20 of HER2 are the most common HER2 mutations in patients with non-small cell lung cancer (NSCLC), a disease in which approved EGFR/HER2 tyrosine kinase inhibitors (TKI) display poor efficiency and undesirable side effects due to their strong inhibition of wild-type (WT) EGFR. Here, we report a HER2-selective covalent TKI, JBJ-08-178-01, that targets multiple HER2 activating mutations, including exon 20 insertions as well as amplification. JBJ-08-178-01 displayed strong selectivity toward HER2 mutants over WT EGFR compared with other EGFR/HER2 TKIs. Determination of the crystal structure of HER2 in complex with JBJ-08-178-01 suggests that an interaction between the inhibitor and Ser783 may be responsible for HER2 selectivity. The compound showed strong antitumoral activity in HER2-mutant or amplified cancers in vitro and in vivo. Treatment with JBJ-08-178-01 also led to a reduction in total HER2 by promoting proteasomal degradation of the receptor. Taken together, the dual activity of JBJ-08-178-01 as a selective inhibitor and destabilizer of HER2 represents a combination that may lead to better efficacy and tolerance in patients with NSCLC harboring HER2 genetic alterations or amplification. SIGNIFICANCE: This study describes unique mechanisms of action of a new mutant-selective HER2 kinase inhibitor that reduces both kinase activity and protein levels of HER2 in lung cancer.
科研通智能强力驱动
Strongly Powered by AbleSci AI